Natixis Advisors LLC Acquires Shares of 24,905 Incyte Co. (NASDAQ:INCY)

Natixis Advisors LLC acquired a new position in shares of Incyte Co. (NASDAQ:INCY - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 24,905 shares of the biopharmaceutical company's stock, valued at approximately $1,720,000.

Other institutional investors also recently made changes to their positions in the company. Quintet Private Bank Europe S.A. purchased a new position in shares of Incyte in the 4th quarter valued at $26,000. Global X Japan Co. Ltd. lifted its holdings in Incyte by 144.7% in the 4th quarter. Global X Japan Co. Ltd. now owns 389 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 230 shares in the last quarter. Brooklyn Investment Group purchased a new position in Incyte in the 3rd quarter valued at about $30,000. R Squared Ltd acquired a new stake in shares of Incyte during the fourth quarter valued at about $30,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Incyte in the third quarter worth about $33,000. 96.97% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, EVP Sheila A. Denton sold 599 shares of the company's stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $69.99, for a total value of $41,924.01. Following the completion of the transaction, the executive vice president now directly owns 25,848 shares in the company, valued at approximately $1,809,101.52. This represents a 2.26 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Barry P. Flannelly sold 19,807 shares of Incyte stock in a transaction on Friday, March 14th. The stock was sold at an average price of $67.69, for a total transaction of $1,340,735.83. Following the sale, the executive vice president now owns 33,567 shares in the company, valued at $2,272,150.23. This represents a 37.11 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 46,827 shares of company stock valued at $3,322,618. 17.60% of the stock is owned by company insiders.

Remove Ads

Incyte Stock Performance

NASDAQ:INCY traded down $0.70 during midday trading on Tuesday, reaching $62.08. The stock had a trading volume of 2,603,519 shares, compared to its average volume of 2,266,270. The stock has a market capitalization of $12.01 billion, a P/E ratio of 229.93, a PEG ratio of 0.41 and a beta of 0.76. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.97 and a quick ratio of 1.94. Incyte Co. has a 1-year low of $50.35 and a 1-year high of $83.95. The firm's fifty day simple moving average is $70.42 and its 200-day simple moving average is $70.17.

Incyte (NASDAQ:INCY - Get Free Report) last posted its quarterly earnings data on Monday, February 10th. The biopharmaceutical company reported $1.09 EPS for the quarter, missing analysts' consensus estimates of $1.57 by ($0.48). Incyte had a return on equity of 0.05% and a net margin of 0.77%. On average, equities research analysts forecast that Incyte Co. will post 4.86 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on INCY shares. Citigroup cut their price target on shares of Incyte from $97.00 to $88.00 and set a "buy" rating on the stock in a report on Tuesday, February 11th. UBS Group initiated coverage on Incyte in a research note on Tuesday, December 17th. They issued a "neutral" rating and a $77.00 price target for the company. Stifel Nicolaus increased their target price on Incyte from $75.00 to $77.00 and gave the stock a "hold" rating in a report on Monday, February 10th. William Blair downgraded Incyte from an "outperform" rating to a "market perform" rating in a report on Tuesday, March 18th. Finally, Cantor Fitzgerald restated a "neutral" rating on shares of Incyte in a research note on Friday, January 10th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average target price of $74.88.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.